Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: A Mendelian randomization meta-analysis

Molecular Genetics and Metabolism

Volumn 99, Issue 2, 2010, Pages 174-183

  Ioannidis, Anastasios ^a   Ikonomi, Eleni ^a   Dimou, Niki L ^a   Douma, Lelouda ^a   Bagos, Pantelis G ^a  

^a UNIVERSITY OF CENTRAL GREECE   (Greece)

Author keywords

NSR; Genetic epidemiology; IRS 1; Mendelian randomization; Meta analysis; Polycystic ovary syndrome; Random effects

Indexed keywords

INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1;

ARTICLE; CLINICAL TRIAL; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN BLOOD LEVEL; META ANALYSIS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RANDOMIZATION; SYSTEMATIC REVIEW;

FASTING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; MENDELIAN RANDOMIZATION ANALYSIS; MODELS, GENETIC; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, INSULIN;

EID: 73749083468     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.10.013     Document Type: Article

References (113)

1. Ehrmann D.A. Polycystic ovary syndrome. N. Engl. J. Med. 352 (2005) 1223-1236
2. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., and Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89 (2004) 2745-2749
3. Pasquali R., and Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann. N. Y. Acad. Sci. 1092 (2006) 158-174
4. Norman R.J., Dewailly D., Legro R.S., and Hickey T.E. Polycystic ovary syndrome. Lancet 370 (2007) 685-697
5. Asuncion M., Calvo R.M., San Millan J.L., Sancho J., Avila S., and Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85 (2000) 2434-2438
6. Diamanti-Kandarakis E., Kouli C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., Zapanti E.D., and Bartzis M.I. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84 (1999) 4006-4011
7. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J. Clin. Endocrinol. Metab. 83 (1998) 3078-3082
8. Chen X., Yang D., Mo Y., Li L., Chen Y., and Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur. J. Obstet. Gynecol. Reprod. Biol. 139 (2008) 59-64
9. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 10 (2008) e3
10. Elghblawl E. Polycystic ovary syndrome and female reproduction. Br. J. Nurs. 16 (2007) 1118-1121
11. Hunter M.H., and Sterrett J.J. Polycystic ovary syndrome: it's not just infertility. Am. Fam. Physician 62 (2000) 1079-1088 1090
12. Essah P.A., Wickham E.P., and Nestler J.E. The metabolic syndrome in polycystic ovary syndrome. Clin. Obstet. Gynecol. 50 (2007) 205-225
13. Diamanti-Kandarakis E., and Economou F. Stress in women: metabolic syndrome and polycystic ovary syndrome. Ann. N. Y. Acad. Sci. 1083 (2006) 54-62
14. Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin. Reprod. Med. 26 (2008) 39-44
15. Urbanek M. The genetics of the polycystic ovary syndrome. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 103-111
16. Luque-Ramirez M., San Millan J.L., and Escobar-Morreale H.F. Genomic variants in polycystic ovary syndrome. Clin. Chim. Acta 366 (2006) 14-26
17. Diamanti-Kandarakis E., and Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum. Reprod. Update 11 (2005) 631-643
18. Poretsky L., Smith D., Seibel M., Pazianos A., Moses A.C., and Flier J.S. Specific insulin binding sites in human ovary. J. Clin. Endocrinol. Metab. 59 (1984) 809-811
19. Poretsky L., Cataldo N.A., Rosenwaks Z., and Giudice L.C. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 20 (1999) 535-582
20. Seino S., Seino M., and Bell G.I. Human insulin-receptor gene. Partial sequence and amplification of exons by polymerase chain reaction. Diabetes 39 (1990) 123-128
21. Taylor S.I., Kadowaki T., Kadowaki H., Accili D., Cama A., and McKeon C. Mutations in insulin-receptor gene in insulin-resistant patients. Diabetes Care 13 (1990) 257-279
22. Moller D.E., Yokota A., White M.F., Pazianos A.G., and Flier J.S. A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance. J. Biol. Chem. 265 (1990) 14979-14985
23. Panz V.R., Ruff P., Joffe B.I., Kedda M.A., and Seftel H.C. SSCP analysis of the tyrosine kinase domain of the insulin receptor gene: polymorphisms detected in South African black and white subjects. Hum. Genet. 97 (1996) 438-440
24. Talbot J.A., Bicknell E.J., Rajkhowa M., Krook A., O'Rahilly S., and Clayton R.N. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 81 (1996) 1979-1983
25. Siegel S., Futterweit W., Davies T.F., Concepcion E.S., Greenberg D.A., Villanueva R., and Tomer Y. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil. Steril. 78 (2002) 1240-1243
26. Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F., Eberle A., Morrow L.A., Moses A.C., and Flier J.S. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes 43 (1994) 247-255
27. Amato P., and Simpson J.L. The genetics of polycystic ovary syndrome. Best Pract. Res. Clin. Obstet. Gynaecol. 18 (2004) 707-718
28. Conway G.S., Avey C., and Rumsby G. The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome. Hum. Reprod. (Oxford, England) 9 (1994) 1681-1683
29. Chen Z.J., Shi Y.H., Zhao Y.R., Li Y., Tang R., Zhao L.X., and Chang Z.H. Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 39 (2004) 582-585
30. Lee E.J., Yoo K.J., Kim S.J., Lee S.H., Cha K.Y., and Baek K.H. Single nucleotide polymorphism in exon 17 of the insulin receptor gene is not associated with polycystic ovary syndrome in a Korean population. Fertil. Steril. 86 (2006) 380-384
31. Lee E.J., Oh B., Lee J.Y., Kimm K., Lee S.H., and Baek K.H. A novel single nucleotide polymorphism of INSR gene for polycystic ovary syndrome. Fertil. Steril. 89 (2008) 1213-1220
32. Saltiel A.R. Diverse signaling pathways in the cellular actions of insulin. Am. J. Physiol. 270 (1996) E375-E385
33. Sesti G., Federici M., Hribal M.L., Lauro D., Sbraccia P., and Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 15 (2001) 2099-2111
34. Garcia P., Shoelson S.E., George S.T., Hinds D.A., Goldberg A.R., and Miller W.T. Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro. J. Biol. Chem. 268 (1993) 25146-25151
35. Ogihara T., Isobe T., Ichimura T., Taoka M., Funaki M., Sakoda H., Onishi Y., Inukai K., Anai M., Fukushima Y., Kikuchi M., Yazaki Y., Oka Y., and Asano T. 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J. Biol. Chem. 272 (1997) 25267-25274
36. Witchel S.F., Smith R., Tomboc M., and Aston C.E. Candidate gene analysis in premature pubarche and adolescent hyperandrogenism. Fertil. Steril. 75 (2001) 724-730
37. El Mkadem S.A., Lautier C., Macari F., Molinari N., Lefebvre P., Renard E., Gris J.C., Cros G., Daures J.P., Bringer J., White M.F., and Grigorescu F. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes 50 (2001) 2164-2168
38. Sir-Petermann T., Perez-Bravo F., Angel B., Maliqueo M., Calvillan M., and Palomino A. G972R polymorphism of IRS-1 in women with polycystic ovary syndrome. Diabetologia 44 (2001) 1200-1201
39. Sir-Petermann T., Angel B., Maliqueo M., Santos J.L., Riesco M.V., Toloza H., and Perez-Bravo F. Insulin secretion in women who have polycystic ovary syndrome and carry the Gly972Arg variant of insulin receptor substrate-1 in response to a high-glycemic or low-glycemic carbohydrate load. Nutrition (Burbank, Los Angeles County, Calif.) 20 (2004) 905-910
40. Dilek S., Ertunc D., Tok E.C., Erdal E.M., and Aktas A. Association of Gly972Arg variant of insulin receptor substrate-1 with metabolic features in women with polycystic ovary syndrome. Fertil. Steril. 84 (2005) 407-412
41. Villuendas G., Botella-Carretero J.I., Roldan B., Sancho J., Escobar-Morreale H.F., and San Millan J.L. Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. Hum. Reprod. (Oxford, England) 20 (2005) 3184-3191
42. Witchel S.F., Kahsar-Miller M., Aston C.E., White C., and Azziz R. Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess. Fertil. Steril. 83 (2005) 371-375
43. Haap M., Machicao F., Stefan N., Thamer C., Tschritter O., Schnuck F., Wallwiener D., Stumvoll M., Haring H.U., and Fritsche A. Genetic determinants of insulin action in polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes 113 (2005) 275-281
44. Lin T.C., Yen J.M., Gong K.B., Kuo T.C., Ku D.C., Liang S.F., and Wu M.J. Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst the Taiwanese population- not correlated with insulin receptor substrate-1 Gly972Arg/Ala513Pro polymorphism. BMC Med. Genet. 7 (2006) 36
45. Baba T., Endo T., Sata F., Honnma H., Kitajima Y., Hayashi T., Manase K., Kanaya M., Yamada H., Minakami H., Kishi R., and Saito T. Polycystic ovary syndrome is associated with genetic polymorphism in the insulin signaling gene IRS-1 but not ENPP1 in a Japanese population. Life Sci. 81 (2007) 850-854
46. Valdes P., Cerda A., Barrenechea C., Kehr M., Soto C., and Salazar L.A. No association between common Gly972Arg variant of the insulin receptor substrate-1 and polycystic ovary syndrome in Southern Chilean women. Clin. Chim. Acta 390 (2008) 63-66
47. Stumvoll M., Fritsche A., Volk A., Stefan N., Madaus A., Maerker E., Teigeler A., Koch M., Machicao F., and Haring H. The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans. Diabetes 50 (2001) 882-885
48. Federici M., Hribal M.L., Ranalli M., Marselli L., Porzio O., Lauro D., Borboni P., Lauro R., Marchetti P., Melino G., and Sesti G. The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. FASEB J. 15 (2001) 22-24
49. Pan Z., Trikalinos T.A., Kavvoura F.K., Lau J., and Ioannidis J.P. Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med. 2 (2005) e334
50. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., and Thacker S.B. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000) 2008-2012
51. Conn V.S., Valentine J.C., Cooper H.M., and Rantz M.J. Grey literature in meta-analyses. Nurs. Res. 52 (2003) 256-261
52. Petiti D.B. Meta-analysis Decision Analysis and Cost-Effectiveness Analysis (1994), Oxford University Press
53. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
54. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986) 177-188
55. Bagos P.G. A unification of multivariate methods for meta-analysis of genetic association studies. Stat. Appl. Genet. Mol. Biol. 7 (2008) Article31
56. Bagos P.G., and Nikolopoulos G.K. A method for meta-analysis of case-control genetic association studies using logistic regression. Stat. Appl. Genet. Mol. Biol. 6 (2007) Article17
57. Minelli C., Thompson J.R., Abrams K.R., Thakkinstian A., and Attia J. The choice of a genetic model in the meta-analysis of molecular association studies. Int. J. Epidemiol. 34 (2005) 1319-1328
58. Trikalinos T.A., Salanti G., Khoury M.J., and Ioannidis J.P. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am. J. Epidemiol. 163 (2006) 300-309
59. Minelli C., Thompson J.R., Tobin M.D., and Abrams K.R. An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. Am. J. Epidemiol. 160 (2004) 445-452
60. Thompson J.R., Minelli C., Abrams K.R., Tobin M.D., and Riley R.D. Meta-analysis of genetic studies using Mendelian randomization-a multivariate approach. Stat. Med. 24 (2005) 2241-2254
61. McGettrick A.J., Feener E.P., and Kahn C.R. Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. J. Biol. Chem. 280 (2005) 6441-6446
62. Almind K., Inoue G., Pedersen O., and Kahn C.R. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J. Clin. Invest. 97 (1996) 2569-2575
63. Sheehan N.A., Didelez V., Burton P.R., and Tobin M.D. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med. 5 (2008) e177
64. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994) 1088-1101
65. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
66. Thompson S.G., and Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat. Med. 18 (1999) 2693-2708
67. Lau J., Schmid C.H., and Chalmers T.C. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J. Clin. Epidemiol. 48 (1995) 45-57 discussion 59-60
68. Lau J., Antman E.M., Jimenez-Silva J., Kupelnick B., Mosteller F., and Chalmers T.C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N. Engl. J. Med. 327 (1992) 248-254
69. Ioannidis J.P., and Trikalinos T.A. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. J. Clin. Epidemiol. 58 (2005) 543-549
70. Rotterdam ESHRE/ASRM-Sponsored PCOS Consenus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil. Steril. 81 (2004) 19-25.
71. Ehrmann D.A., Tang X., Yoshiuchi I., Cox N.J., and Bell G.I. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87 (2002) 4297-4300
72. Ertunc D., Tok E.C., Aktas A., Erdal E.M., and Dilek S. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. Hum. Reprod. 20 (2005) 1207-1212
73. Jin L., Zhu X.M., Luo Q., Qian Y., Jin F., and Huang H.F. A novel SNP at exon 17 of INSR is associated with decreased insulin sensitivity in Chinese women with PCOS. Mol. Hum. Reprod. 12 (2006) 151-155
74. Jin L., Huang H.F., Jin F., and Qian Y.L. Polymorphism in insulin receptor gene exon 17 in women with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 40 (2005) 323-326
75. Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y., Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., et al. Detection of mutations in the insulin receptor gene in patients with insulin resistance by analysis of single-stranded conformational polymorphisms. Diabetologia 35 (1992) 261-266
76. Tucci S., Futterweit W., Concepcion E.S., Greenberg D.A., Villanueva R., Davies T.F., and Tomer Y. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J. Clin. Endocrinol. Metab. 86 (2001) 446-449
77. Urbanek M., Legro R.S., Driscoll D.A., Azziz R., Ehrmann D.A., Norman R.J., Strauss III J.F., Spielman R.S., and Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc. Natl. Acad. Sci. USA 96 (1999) 8573-8578
78. Villuendas G., Escobar-Morreale H.F., Tosi F., Sancho J., Moghetti P., and San Millan J.L. Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. Fertil. Steril. 79 (2003) 219-220
79. Stewart D.R., Dombroski B.A., Urbanek M., Ankener W., Ewens K.G., Wood J.R., Legro R.S., Strauss III J.F., Dunaif A., and Spielman R.S. Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J. Clin. Endocrinol. Metab. 91 (2006) 4112-4117
80. Bagos P.G. Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in Polycystic Ovary Syndrome. Mol. Hum. Reprod. 15 (2008) 19-26
81. Crosignani P.G., and Nicolosi A.E. Polycystic ovarian disease: heritability and heterogeneity. Hum. Reprod. Update 7 (2001) 3-7
82. Kashar-Miller M., and Azziz R. Heritability and the risk of developing androgen excess. J. Steroid Biochem. Mol. Biol. 69 (1999) 261-268
83. Thompson S.G., and Higgins J.P. How should meta-regression analyses be undertaken and interpreted?. Stat. Med. 21 (2002) 1559-1573
84. Schmid C.H., Stark P.C., Berlin J.A., Landais P., and Lau J. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J. Clin. Epidemiol. 57 (2004) 683-697
85. Higgins J.P., and Thompson S.G. Controlling the risk of spurious findings from meta-regression. Stat. Med. 23 (2004) 1663-1682
86. Bloom M.S., Schisterman E.F., and Hediger M.L. Selecting controls is not selecting "normals": design and analysis issues for studying the etiology of polycystic ovary syndrome. Fertil. Steril. 86 (2006) 1-12
87. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
88. Galluzzo A., Amato M.C., and Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr. Metab. Cardiovasc. Dis. 18 (2008) 511-518
89. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 30 (2006) 13-17
90. Marchetti P., Lupi R., Federici M., Marselli L., Masini M., Boggi U., Del Guerra S., Patane G., Piro S., Anello M., Bergamini E., Purrello F., Lauro R., Mosca F., Sesti G., and Del Prato S. Insulin secretory function is impaired in isolated human islets carrying the Gly(972)→Arg IRS-1 polymorphism. Diabetes 51 (2002) 1419-1424
91. Hribal M.L., Tornei F., Pujol A., Menghini R., Barcaroli D., Lauro D., Amoruso R., Lauro R., Bosch F., Sesti G., and Federici M. Transgenic mice overexpressing human G972R IRS-1 show impaired insulin action and insulin secretion. J. Cell. Mol. Med. 12 (2008) 2096-2106
92. Kulkarni R.N. Receptors for insulin and insulin-like growth factor-1 and insulin receptor substrate-1 mediate pathways that regulate islet function. Biochem. Soc. Trans. 30 (2002) 317-322
93. Kaihara A., Kawai Y., Sato M., Ozawa T., and Umezawa Y. Locating a protein-protein interaction in living cells via split Renilla luciferase complementation. Anal. Chem. 75 (2003) 4176-4181
94. Jellema A., Zeegers M.P., Feskens E.J., Dagnelie P.C., and Mensink R.P. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies. Diabetologia 46 (2003) 990-995
95. Book C.B., and Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 84 (1999) 3110-3116
96. Wu X.K., Zhou S.Y., Liu J.X., Pollanen P., Sallinen K., Makinen M., and Erkkola R. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil. Steril. 80 (2003) 954-965
97. Carvalho C.R., Carvalheira J.B., Lima M.H., Zimmerman S.F., Caperuto L.C., Amanso A., Gasparetti A.L., Meneghetti V., Zimmerman L.F., Velloso L.A., and Saad M.J. Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways. Endocrinology 144 (2003) 638-647
98. Lima M.H., Souza L.C., Caperuto L.C., Bevilacqua E., Gasparetti A.L., Zanuto R., Saad M.J., and Carvalho C.R. Up-regulation of the phosphatidylinositol 3-kinase/protein kinase B pathway in the ovary of rats by chronic treatment with hCG and insulin. J. Endocrinol. 190 (2006) 451-459
99. Zhang G., Garmey J.C., and Veldhuis J.D. Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase/17, 20-lyase (CYP17) genes in porcine theca cells. Endocrinology 141 (2000) 2735-2742
100. Rondinone C.M., Wang L.M., Lonnroth P., Wesslau C., Pierce J.H., and Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. USA 94 (1997) 4171-4175
101. Yen H.W., Jakimiuk A.J., Munir I., and Magoffin D.A. Selective alterations in insulin receptor substrates-1, -2 and -4 in theca but not granulosa cells from polycystic ovaries. Mol. Hum. Reprod. 10 (2004) 473-479
102. Wu X., Sallinen K., Anttila L., Makinen M., Luo C., Pollanen P., and Erkkola R. Expression of insulin-receptor substrate-1 and -2 in ovaries from women with insulin resistance and from controls. Fertil. Steril. 74 (2000) 564-572
103. Kaburagi Y., Yamashita R., Ito Y., Okochi H., Yamamoto-Honda R., Yasuda K., Sekihara H., Sasazuki T., Kadowaki T., and Yazaki Y. Insulin-induced cell cycle progression is impaired in chinese hamster ovary cells overexpressing insulin receptor substrate-3. Endocrinology 145 (2004) 5862-5874
104. Vignesh J.P., and Mohan V. Polycystic ovary syndrome: a component of metabolic syndrome?. J. Postgrad. Med. 53 (2007) 128-134
105. Mukherjee S., Shaikh N., Khavale S., Shinde G., Meherji P., Shah N., and Maitra A. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. Eur. J. Endocrinol. 160 (2009) 855-862
106. Lawlor D.A., Harbord R.M., Sterne J.A., Timpson N., and Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat. Med. 27 (2008) 1133-1163
107. Bremer A.A., and Miller W.L. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil. Steril. 89 (2008) 1039-1048
108. Bogaert V., Vanbillemont G., Taes Y., De Bacquer D., Deschepper E., Van Steen K., and Kaufman J.M. Small effect of the androgen receptor gene GGN repeat polymorphism on serum testosterone levels in healthy men. Eur. J. Endocrinol. 161 (2009) 171-177
109. Mohlig M., Jurgens A., Spranger J., Hoffmann K., Weickert M.O., Schlosser H.W., Schill T., Brabant G., Schuring A., Pfeiffer A.F., Gromoll J., and Schofl C. The androgen receptor CAG repeat modifies the impact of testosterone on insulin resistance in women with polycystic ovary syndrome. Eur. J. Endocrinol. 155 (2006) 127-130
110. Van Nieuwerburgh F., Stoop D., Cabri P., Dhont M., Deforce D., and De Sutter P. Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome. Gynecol. Endocrinol. 24 (2008) 669-673
111. N. Xita, L. Lazaros, I. Georgiou, A. Tsatsoulis, CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype, Fertil. Steril. (2009), in press.
112. Carey A.H., Waterworth D., Patel K., White D., Little J., Novelli P., Franks S., and Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet. 3 (1994) 1873-1876
113. Unsal T., Konac E., Yesilkaya E., Yilmaz A., Bideci A., Ilke Onen H., Cinaz P., and Menevse A. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J. Assist. Reprod. Genet. 26 (2009) 205-216